Last reviewed 2026-04-20 · How we verify

dAd5GNE Vaccine

Weill Medical College of Cornell University · Phase 1 active Biologic Quality 0/100

dAd5GNE Vaccine is a Biologic drug developed by Weill Medical College of Cornell University. It is currently in Phase 1 development.

At a glance

Generic name	dAd5GNE Vaccine
Sponsor	Weill Medical College of Cornell University
Modality	Biologic
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Safety Study of a Disrupted Adenovirus (Ad) Serotype Cocaine Vaccine for Cocaine-dependent Individuals (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

dAd5GNE Vaccine CI brief — competitive landscape report
dAd5GNE Vaccine updates RSS · CI watch RSS
Weill Medical College of Cornell University portfolio CI

Frequently asked questions about dAd5GNE Vaccine

What is dAd5GNE Vaccine?

dAd5GNE Vaccine is a Biologic drug developed by Weill Medical College of Cornell University.

Who makes dAd5GNE Vaccine?

dAd5GNE Vaccine is developed by Weill Medical College of Cornell University (see full Weill Medical College of Cornell University pipeline at /company/weill-medical-college-of-cornell-university).

What development phase is dAd5GNE Vaccine in?

dAd5GNE Vaccine is in Phase 1.

Manufacturer: Weill Medical College of Cornell University — full pipeline
Compare: dAd5GNE Vaccine vs similar drugs
Pricing: dAd5GNE Vaccine cost, discount & access